Anirudh Rao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anirudh Rao has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Hunter Groninger
MedStar Washington Hospital Center, Washington, USA
9 shared publications Hunter Groninger
Department of Medicine, MedStar Washington Hospital Center, Washington, DC; Georgetown University School of Medicine, Washington, DC
6 shared publicationsFarooq H. Sheikh
MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC; Georgetown University School of Medicine, Washington, DC
4 shared publications- Kelley M. Anderson
School of Nursing, University of Virginia, 225 Jeanette Lancaster Lane, McLeod Hall, Charlottesville, VA 22903, United States
4 shared publications Kelley M. Anderson
University of Virginia School of Nursing, Charlottesville, VA
3 shared publicationsManavotam Singh
Medstar Heart and Vascular Institute, Washington, DC, USA
3 shared publications
Latest Publications
- 11 December 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (8) , 1337-1346
Factors Associated With Outpatient Palliative Care Use in Patients With Long-Term Left Ventricular Assist Device (LVAD) Use
- 11 December 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (8) , 1337-1346
Factors Associated With Outpatient Palliative Care Use in Patients With Long-Term Left Ventricular Assist Device (LVAD) Use
- 10 October 2025
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 28 (10) , 1377-1379
Outcomes of Heart Failure Patients on Palliative Inotrope Therapy in the Hospice Setting: A Single Center Retrospective Cohort Study
Background: Chronic intravenous inotropic support (CIIS) is recommended as palliative therapy for end-stage heart failure (HF) but is underutilized in hospice settings. Objectives: This study evaluates outcomes for patients on CIIS receiving hospice care. Design: Retrospective cohort study using electronic health records of patients on CIIS admitted to hospice. Setting/Subjects: Twenty-one patients admitted to a mid-Atlantic hospice between 2018 and 2022. Measurements: Data collected included demographics, inotropic therapy details, hospice length of stay (LOS), hospitalizations, and medication usage. Results: The mean age was 72.9 years; 67% were on milrinone. Patients had a mean hospice LOS of 49.6 days, with 66% experiencing no hospitalizations. Only 24% of patients required high-dose opioids. 24% of patients were discharged alive from hospice, and 52% died at home. Conclusion: Caring for patients on CIIS in hospice appears feasible and may portend some benefits to patients. Further research is warranted to confirm these findings in a prospective observational cohort.
- 10 October 2025
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 28 (10) , 1377-1379
Outcomes of Heart Failure Patients on Palliative Inotrope Therapy in the Hospice Setting: A Single Center Retrospective Cohort Study
Background: Chronic intravenous inotropic support (CIIS) is recommended as palliative therapy for end-stage heart failure (HF) but is underutilized in hospice settings. Objectives: This study evaluates outcomes for patients on CIIS receiving hospice care. Design: Retrospective cohort study using electronic health records of patients on CIIS admitted to hospice. Setting/Subjects: Twenty-one patients admitted to a mid-Atlantic hospice between 2018 and 2022. Measurements: Data collected included demographics, inotropic therapy details, hospice length of stay (LOS), hospitalizations, and medication usage. Results: The mean age was 72.9 years; 67% were on milrinone. Patients had a mean hospice LOS of 49.6 days, with 66% experiencing no hospitalizations. Only 24% of patients required high-dose opioids. 24% of patients were discharged alive from hospice, and 52% died at home. Conclusion: Caring for patients on CIIS in hospice appears feasible and may portend some benefits to patients. Further research is warranted to confirm these findings in a prospective observational cohort.
- Open Access
- 23 September 2025
- Published by Elsevier in Journal of Cardiac Failure - Intersections
- Vol. 1 (2) , 129-137
“It’s Done its Job”: A Qualitative Study of Interprofessional Clinicians’ Perspectives on LVAD Deactivation
- 23 September 2025
- Published by Elsevier in Journal of Cardiac Failure - Intersections
- Vol. 1 (2) , 129-137
Open Access“It’s Done its Job”: A Qualitative Study of Interprofessional Clinicians’ Perspectives on LVAD Deactivation
- Open Access
- 30 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101835
Interprofessional Clinician Perspectives on LVAD Deactivation Compared to Dialysis Discontinuation
- 30 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101835
Open AccessInterprofessional Clinician Perspectives on LVAD Deactivation Compared to Dialysis Discontinuation
- 23 March 2025
- Published by SAGE Publications in Journal of Intensive Care Medicine
- Vol. 40 (8) , 885-892
A Retrospective Cohort Study of the Role of Palliative Care Consultation for Patients on Extracorporeal Membrane Oxygenation
Background: Extracorporeal membrane oxygenation (ECMO) serves as a critical intervention for patients with severe cardiac and pulmonary dysfunction. Given the high rates of mortality and morbidity, as well as the impact on families, palliative care (PC) integration is recommended. We aimed to examine the indications and outcomes of ECMO patients at a tertiary care hospital and evaluate the impact of PC consultation on patient outcomes. Methods: We conducted a retrospective cohort study of 306 patients cannulated for venovenous (VV) or venoarterial (VA) ECMO from January 2020 to December 2022. We analyzed demographics, ECMO indications, and outcomes, comparing those who received PC consultations with those who did not. Results: Of the 306 patients analyzed, 220 were on VA-ECMO and 86 on VV-ECMO. The overall in-hospital mortality rate was 49%. Patients on VV-ECMO had longer ECMO durations (8 vs 4 days) and hospital stays (31 vs 16 days, P < 0.001) than patients on VA-ECMO. PC consultations were associated with increased ECMO duration and hospital stay in both groups (P < 0.001). Mortality among patients who received PC consultations was not statistically different from those who did not (P = 0.68). Notably, patients with obesity on VA-ECMO had 2.3 times higher odds of in-hospital death (P = 0.027). Conclusion: PC consultation is integral in managing patients on ECMO, focusing on holistic support for patients and their families. Further prospective studies are warranted to explore the psychosocial benefits of PC for patients on ECMO and their family members.
- 23 March 2025
- Published by SAGE Publications in Journal of Intensive Care Medicine
- Vol. 40 (8) , 885-892
A Retrospective Cohort Study of the Role of Palliative Care Consultation for Patients on Extracorporeal Membrane Oxygenation
Background: Extracorporeal membrane oxygenation (ECMO) serves as a critical intervention for patients with severe cardiac and pulmonary dysfunction. Given the high rates of mortality and morbidity, as well as the impact on families, palliative care (PC) integration is recommended. We aimed to examine the indications and outcomes of ECMO patients at a tertiary care hospital and evaluate the impact of PC consultation on patient outcomes. Methods: We conducted a retrospective cohort study of 306 patients cannulated for venovenous (VV) or venoarterial (VA) ECMO from January 2020 to December 2022. We analyzed demographics, ECMO indications, and outcomes, comparing those who received PC consultations with those who did not. Results: Of the 306 patients analyzed, 220 were on VA-ECMO and 86 on VV-ECMO. The overall in-hospital mortality rate was 49%. Patients on VV-ECMO had longer ECMO durations (8 vs 4 days) and hospital stays (31 vs 16 days, P < 0.001) than patients on VA-ECMO. PC consultations were associated with increased ECMO duration and hospital stay in both groups (P < 0.001). Mortality among patients who received PC consultations was not statistically different from those who did not (P = 0.68). Notably, patients with obesity on VA-ECMO had 2.3 times higher odds of in-hospital death (P = 0.027). Conclusion: PC consultation is integral in managing patients on ECMO, focusing on holistic support for patients and their families. Further prospective studies are warranted to explore the psychosocial benefits of PC for patients on ECMO and their family members.
- 4 March 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (3) , 599
Ethical and Moral Complexities of Left Ventricular Assist Device Deactivation
- 4 March 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (3) , 599
Ethical and Moral Complexities of Left Ventricular Assist Device Deactivation
- 19 November 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (3) , 274-278
The Complex Ethical and Moral Experience of Left Ventricular Assist Device Deactivation
- 19 November 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (3) , 274-278
The Complex Ethical and Moral Experience of Left Ventricular Assist Device Deactivation
- 1 October 2023
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 26 (10) , 1428-1434
Clinical Protocol for Left Ventricular Assist Device Deactivation at End of Life
As patients live longer with left ventricular assist device (LVAD) support, many will either suffer an acute event or develop a gradual, progressive disease that results in a terminal prognosis. At the end-of-life, patients, and more often, their families, will be faced with the decision to deactivate the LVAD to allow natural death. The process of LVAD deactivation carries some distinct features that distinguish it from withdrawal of other forms of life-sustaining medical technology: multidisciplinary collaboration is paramount; prognosis after deactivation is short, typically minutes-hours; and premedication doses of symptom-focused medications are typically higher than other situations involving withdrawal of life-sustaining medical technologies given the precipitous decline in cardiac output following LVAD deactivation. In this Case Discussion, we introduce the complexity of planned in-hospital LVAD deactivation through a clinical case, share our detailed institutional checklist and order set for LVAD deactivation, and broach multidisciplinary clinical protocol development processes.
- 1 October 2023
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 26 (10) , 1428-1434
Clinical Protocol for Left Ventricular Assist Device Deactivation at End of Life
As patients live longer with left ventricular assist device (LVAD) support, many will either suffer an acute event or develop a gradual, progressive disease that results in a terminal prognosis. At the end-of-life, patients, and more often, their families, will be faced with the decision to deactivate the LVAD to allow natural death. The process of LVAD deactivation carries some distinct features that distinguish it from withdrawal of other forms of life-sustaining medical technology: multidisciplinary collaboration is paramount; prognosis after deactivation is short, typically minutes-hours; and premedication doses of symptom-focused medications are typically higher than other situations involving withdrawal of life-sustaining medical technologies given the precipitous decline in cardiac output following LVAD deactivation. In this Case Discussion, we introduce the complexity of planned in-hospital LVAD deactivation through a clinical case, share our detailed institutional checklist and order set for LVAD deactivation, and broach multidisciplinary clinical protocol development processes.
- 22 August 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 205, 231-233
Health-Related Quality of Life in Patients with Advanced Heart Failure Receiving Continuous Intravenous Inotropic Support: A Multi-Center Survey
- 22 August 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 205, 231-233
Health-Related Quality of Life in Patients with Advanced Heart Failure Receiving Continuous Intravenous Inotropic Support: A Multi-Center Survey
- 5 August 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 66 (5) , 561-569.e2
Determinants of Health and Outcomes in Medicare Recipients With Heart Disease: A Population Study
- 5 August 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 66 (5) , 561-569.e2
Determinants of Health and Outcomes in Medicare Recipients With Heart Disease: A Population Study